In vitro characterization of microcontainers as an oral drug delivery system. by Nielsen, Line Hagner et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
In vitro characterization of microcontainers as an oral drug delivery system.
Nielsen, Line Hagner; Keller, Stephan Sylvest; Petersen, Ritika Singh; Jacobsen, J.; Boisen, Anja;
Müllertz, A.
Publication date:
2014
Document Version
Peer reviewed version
Link back to DTU Orbit
Citation (APA):
Nielsen, L. H., Keller, S. S., Petersen, R. S., Jacobsen, J., Boisen, A., & Müllertz, A. (2014). In vitro
characterization of microcontainers as an oral drug delivery system.. Abstract from 41th Annual Meeting and
amp, Chicago, United States.
In vitro characterization of microcontainers as an oral drug delivery system 
 
L. Hagner Nielsen
1,2
, S. Sylvest Keller
1
, R. Singh
1
, J. Jacobsen
2
, A. Boisen
1
, A. Müllertz
2,3
 
 
1
Department of Micro- and Nanotechnology, Technical University of Denmark, Kongens Lyngby, 2800, 
Denmark; 3Bioneer:FARMA, 2Department of Pharmacy, Faculty of Health and Medical Sciences, 
University of Copenhagen, Copenhagen, 2100, Denmark 
line.hagner@sund.ku.dk 
 
ABSTRACT SUMMARY 
We here present in vitro studies showing the 
promise of microcontainers (fabricated in either 
SU-8 or Poly(lactic acid) (PLLA)) as an oral 
drug delivery system for the poorly water-
soluble drug, furosemide. 
 
INTRODUCTION 
Micro fabricated drug delivery devices have 
been proposed as an approach for delivering 
drugs orally as they can protect the drug through 
the stomach and thereby, possibly improve the 
oral bioavailability
1,2
. Microcontainers are 
polymeric devices consisting of a flat base with 
a walled reservoir
2,3
. The microcontainers are 
characterized by enabling unidirectional release 
directly to the intestinal mucosa, as only one 
side of the microcontainers is open. The cavity 
of the microcontainers is filled with drug and 
subsequently, coated with a lid of a pH-sensitive 
polymer to protect the drug from degradation 
and premature release in the stomach. After 
emptying into the duodenum, the polymer lid 
will dissolve at the higher pH in the small 
intestine and the drug is released and absorbed 
through the intestinal wall (Figure 1). 
The purpose of this study was to in vitro 
characterize the microcontainers as an 
innovative oral drug delivery system for the 
poorly water-soluble drug, furosemide. 
 
Figure 1. A) Fabrication of microcontainers in 
either SU-8 or PLLA. B) Filling with 
amorphous furosemide salt. C) Spray coating of 
a lid of Eudragit L100. D) Dissolution of 
coating and release of drug. 
 
EXPERIMENTAL METHODS 
Prototype microcontainers with inner 
diameters of 230 µm were fabricated using 
epoxy resins (SU-8, Microchem, USA) 
patterned through two steps of photolithography 
defining the bottom and the walls of the 
microcontainers (Figure 2A). Alternatively, 
biodegradable microcontainers were prepared in 
(PLLA) by using the technique of hot 
embossing (Figure 2B).  
         
 
Figure 2. Microcontainers fabricated by A) UV 
patterning of SU-8 and B) hot embossing in 
PLLA. 
 
The microcontainers were filled with 
amorphous furosemide sodium salt (prepared by 
spray drying
4
) followed by spray coated 
(ExactaCoat, Sono-Tek, USA) with a solution of 
1 wt% Eudragit L100 (Evonik Industries, Essen, 
Germany). The release of the drug from the 
microcontainers was evaluated in a biorelevant 
gastric medium at pH 1.6 and biorelevant 
intestinal medium at pH 6.5. The intestinal 
permeability of the amorphous furosemide salt 
loaded into the microcontainers was evaluated 
using the Caco-2 cell model with biorelevant 
intestinal medium pH 6.5 as the apical medium. 
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RESULTS AND DISCUSSION 
After filling of the microcontainers with 
amorphous furosemide salt (Figure 3a), the 
cavity of the drug-filled microcontainers were 
spray coated with Eudragit L100, resulting in a 
7 µm thick Eudragit layer (Figure 3b).  
 
 
Figure 3. SEM image of a microcontainer a) 
filled with amorphous furosemide salt. b) filled 
with drug and subsequently coated with 7 µm 
Eudragit L100.  
 
From the release experiments, it was observed 
that the Eudragit layer prevented drug release in 
gastric medium, while an immediate release of 
the amorphous furosemide salt was seen in the 
intestinal medium (Figure 4).  
 
Figure 4. Release profiles from microcontainers 
filled with amorphous furosemide salt and 
coated with Eudragit L100 in gastric medium 
pH 1.6 and intestinal medium pH 6.5. Data 
shown represent the mean of 3 replicates±SD.  
 
The permeability studies showed a fast 
absorption of the amorphous furosemide salt 
with no significant difference between the 
microcontainers (Papp 1.79·10
-5
±0.68·10
-6
 cm/s, 
mean±SD n=11) and bulk powder of amorphous 
furosemide salt (Papp 1.62·10
-5
±1.039·10
-5 
cm/s, 
mean±SD n=11) (Figure 5). 
 
 
 
Figure 5. The intestinal permeability through 
Caco-2 cells of the amorphous furosemide salt 
in bulk form and loaded into microcontainers. 
Data shown represent the mean of 11 
replicates±SD.   
 
CONCLUSION 
Microcontainers were successfully 
fabricated and loaded with powder drug. The 
Eudragit layer prevented drug release in gastric 
medium, and facilitated an immediate release in 
the intestinal medium. Furthermore, the 
amorphous furosemide salt loaded in 
microcontainers was fast absorbed through the 
Caco-2 cell monolayer. Microcontainers 
therefore show considerable future potential as 
oral drug delivery systems. 
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